Finance

Lists
TAKP34:BVMF
Takeda Pharmaceutical Co Ltd BDR
90,54 BRL
0,00%
(0,00) 1D
6-окт., 15:21:39 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for TAKP34...
Mkt. cap
58,89 млд
Avg. vol.
36,00
Volume
0,00
52-wk high
102,65 BRL
52-wk low
70,80 BRL
Shares outstanding
1,60 млд
No. of employees
47 миң
Mkt. cap
58,89 млд
Avg. vol.
36,00
Volume
0,00
52-wk high
102,65 BRL
52-wk low
70,80 BRL
Shares outstanding
1,60 млд
No. of employees
47 миң
News stories
From web sources and news partners
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd BDR
CEOChristophe Weber | Christophe Weber
Employees47 миң
Founded1781-ж., 12-июн.
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Last report
2026-ж., 30-июл.
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
1,22 трлн / 1,15 трлн
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
1,11 трлн
1,19 трлн
1,09 трлн
1,22 трлн
Cost of goods sold
380,06 млд
401,15 млд
453,33 млд
406,68 млд
Cost of revenue
380,06 млд
401,15 млд
453,33 млд
406,68 млд
Research and development expenses
161,48 млд
175,23 млд
187,96 млд
167,40 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
253,55 млд
282,78 млд
291,96 млд
286,51 млд
Operating expense
562,57 млд
661,30 млд
519,65 млд
612,60 млд
Total operating expenses
942,63 млд
1,06 трлн
972,98 млд
1,02 трлн
Operating income
170,17 млд
129,25 млд
121,56 млд
200,62 млд
Other non operating income
77,96 млд
-197,22 млд
181,53 млд
-28,14 млд
EBT including unusual items
28,17 млд
133,86 млд
-455,02 млд
162,72 млд
EBT excluding unusual items
128,86 млд
114,17 млд
71,49 млд
161,92 млд
Income tax expense
39,90 млд
30,13 млд
-86,62 млд
49,46 млд
Effective tax rate
141,64%
22,51%
19,04%
30,40%
Other operating expenses
16,12 млд
67,13 млд
-64,27 млд
53,17 млд
Net income
-11,80 млд
103,64 млд
-368,47 млд
113,20 млд
Net profit margin
-1,06%
8,70%
-33,66%
9,28%
Earnings per share
-
-
-
-
Interest and investment income
43,92 млд
181,35 млд
-
24,61 млд
Interest expense
-161,10 млд
-
-239,63 млд
-35,70 млд
Net interest expenses
-117,18 млд
181,35 млд
-239,63 млд
-11,09 млд
Depreciation and amortization charges
-
-
-
-
EBITDA
355,15 млд
319,89 млд
192,73 млд
363,66 млд
Gain or loss from assets sale
303,00 млн
358,00 млн
1,46 млд
-6,00 млд
AI content may include mistakes. Learn more
Google колдонмолору